Objectives Secukinumab (SEC), a fully human monoclonal antibody that selectively
neutralizes interleukin (IL)-17A, has been approved in Greece for the treatment of Psoriasis
(PsO), Psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS). This study assessed the
budget impact of introduction of SEC to the market, for treatment across the three indications
from the Greek healthcare payer's perspective. Methods A cross indication budget impact
model was developed and adapted to estimate the cost of resource use of introducing SEC …